SkyePharma faces European delay with Flutiform
This article was originally published in Scrip
Executive Summary
SkyePharma is facing delays with the review of its European marketing authorisation application (MAA) for Flutiform (fluticasone propionate plus formoterol fumarate), "due to lack of complete consensus by the concerned member states (CMS) within the timescale laid down by the decentralised review procedure", it said.